U.S. Markets open in 9 hrs 14 mins

Jiangsu Hengrui Medicine Co., Ltd. (600276.SS)

Shanghai - Shanghai Delayed Price. Currency in CNY
Add to watchlist
37.00-0.44 (-1.18%)
As of 11:29AM CST. Market open.

Jiangsu Hengrui Medicine Co., Ltd.

38 Huanghe Rd Eco & Tech Dev Park
Lianyungang 222000
86 518 8122 0983

IndustryDrug Manufacturers—General
Full Time Employees24,491

Key Executives

NameTitlePayExercisedYear Born
Mr. Jianjun LiuFinancial DirectorN/AN/A1978
Ms. Su Mei JiangExec. Deputy GM & DirectorN/AN/A1965
Mr. Jie Ping SunDeputy GM & DirectorN/AN/A1970
Mr. Hong Bin DaiDeputy GM & DirectorN/AN/A1976
Dr. Lian Shan Zhang Ph.D.Deputy GM & DirectorN/AN/A1962
Mr. Kai Hong YuanDeputy Gen. Mang.N/AN/A1965
Mr. Ya Ping ShenDeputy Gen. Mang.N/AN/A1964
Mr. Xu Gen SunDeputy Gen. Mang.N/AN/A1970
Mr. Wei Kang TaoDeputy Gen. Mang.N/AN/A1964
Mr. Cheng LiaoDeputy Gen. Mang.N/AN/A1975
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.


Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.

Corporate Governance

Jiangsu Hengrui Medicine Co., Ltd.’s ISS Governance QualityScore as of July 1, 2022 is 6. The pillar scores are Audit: 7; Board: 5; Shareholder Rights: 7; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.